Press Releases

01.12.20 Hyloris reinforces its Board of Directors with the nomination of Chris Buyse
EN
FR
27.11.20 Information on the total number of voting rights and shares – additional thresholds
EN
FR
04.11.20 Distribution agreements for Maxigesic® IV in the UK and Hong Kong
EN
FR
27.10.20 Hyloris to present at upcoming European investor conferences
EN
FR
01.10.20 Hyloris appoints Dr. Dietmar Aichhorn as Chief Operating Officer
EN
FR
07.09.20 Hyloris announces approval of Maxigesic®
EN
FR
06.08.20 Hyloris Reports Half-Year 2020 Financial Results and Business Highlights
EN
FR
31.07.20 Publication of transparency notifications
EN
FR
31.07.20 Hyloris Pharmaceuticals announces the end of the stabilisation period
EN
FR
31.07.20 Hyloris Pharmaceuticals – IPO Denominator
EN
FR
30.07.20 Hyloris Pharmaceuticals Notice of Half Year 2020 Results and Conference Call
EN
FR
16.07.20 Hyloris Pharmaceuticals Mid Stabilisation Period Announcement – second period
EN
FR
07.07.20 Hyloris Pharmaceuticals Mid Stabilisation Period Announcement
EN
FR
06.07.20 Publication of Transparency Notifications
EN
FR
30.06.20 Information on the total number of voting rights and shares – additional thresholds
EN
FR
26.06.20 Hyloris Pharmaceuticals Raises approximately EUR 61.81 million in Successful Initial Public Offering
EN
FR
24.06.20 Hyloris Pharmaceuticals Announces Narrowing of Price Range of its Initial Public Offering
EN
FR
19.06.20 Hyloris Pharmaceuticals Announces Coverage of the Maximum Offering Size at the Midpoint of the Price Range
EN
FR
18.06.20 Coverage of the Base Offering of its Initial Public Offering
EN
FR
17.06.20 Hyloris Pharmaceuticals launches its Initial Public Offering on Euronext Brussels
EN
FR
03.06.20 Hyloris Pharmaceuticals Announces Intention to Launch an IPO on Euronext Brussels
EN
FR